Cadrenal Therapeutics (CVKD) Competitors $16.45 -0.05 (-0.30%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$16.53 +0.08 (+0.49%) As of 05/2/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. GLSI, FTLF, EDIT, THTX, LYEL, TARA, CGEN, SLS, NMRA, and SCPHShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Greenwich LifeSciences (GLSI), FitLife Brands (FTLF), Editas Medicine (EDIT), Theratechnologies (THTX), Lyell Immunopharma (LYEL), Protara Therapeutics (TARA), Compugen (CGEN), SELLAS Life Sciences Group (SLS), Neumora Therapeutics (NMRA), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Greenwich LifeSciences FitLife Brands Editas Medicine Theratechnologies Lyell Immunopharma Protara Therapeutics Compugen SELLAS Life Sciences Group Neumora Therapeutics scPharmaceuticals Cadrenal Therapeutics (NASDAQ:CVKD) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Do institutionals & insiders have more ownership in CVKD or GLSI? 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 48.6% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher earnings and valuation, CVKD or GLSI? Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$8.36M-$8.67-1.90Greenwich LifeSciencesN/AN/A-$8.89M-$1.20-8.33 Do analysts recommend CVKD or GLSI? Cadrenal Therapeutics presently has a consensus price target of $32.00, indicating a potential upside of 94.53%. Greenwich LifeSciences has a consensus price target of $39.00, indicating a potential upside of 290.39%. Given Greenwich LifeSciences' higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, CVKD or GLSI? Cadrenal Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Does the media refer more to CVKD or GLSI? In the previous week, Greenwich LifeSciences had 3 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 4 mentions for Greenwich LifeSciences and 1 mentions for Cadrenal Therapeutics. Greenwich LifeSciences' average media sentiment score of 0.95 beat Cadrenal Therapeutics' score of 0.50 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Overall Sentiment Cadrenal Therapeutics Positive Greenwich LifeSciences Positive Is CVKD or GLSI more profitable? Cadrenal Therapeutics' return on equity of -142.95% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -142.95% -118.40% Greenwich LifeSciences N/A -185.12%-164.27% Does the MarketBeat Community prefer CVKD or GLSI? Greenwich LifeSciences received 3 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformCadrenal TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesGreenwich LifeSciencesOutperform Votes947.37% Underperform Votes1052.63% SummaryGreenwich LifeSciences beats Cadrenal Therapeutics on 7 of the 13 factors compared between the two stocks. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.91M$6.85B$5.55B$8.02BDividend YieldN/A2.97%5.09%4.23%P/E Ratio-2.467.4422.6918.83Price / SalesN/A257.59404.29106.72Price / CashN/A65.8538.1834.62Price / Book1.866.576.794.33Net Income-$8.36M$143.14M$3.22B$247.97M7 Day Performance-2.08%3.35%3.34%3.16%1 Month Performance-2.20%10.29%6.89%8.10%1 Year PerformanceN/A-3.45%16.09%4.99% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics3.1827 of 5 stars$16.45-0.3%$32.00+94.5%N/A$31.91MN/A-2.464Upcoming EarningsShort Interest ↓News CoverageGLSIGreenwich LifeSciences2.0744 of 5 stars$10.04+0.6%$39.00+288.4%-28.6%$133.27MN/A-12.553Short Interest ↑FTLFFitLife Brands4.0054 of 5 stars$14.42+0.8%$20.50+42.2%+12.2%$132.94M$64.47M17.0720Short Interest ↑EDITEditas Medicine4.2855 of 5 stars$1.58+2.6%$6.54+313.8%-70.8%$132.26M$32.31M-0.62230Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoverageTHTXTheratechnologiesN/A$2.87+3.6%N/A+106.7%$131.96M$88.67M-28.70140Short Interest ↑LYELLyell Immunopharma3.4067 of 5 stars$0.44-2.0%$1.00+126.8%-80.8%$130.24M$61,000.00-0.56270Upcoming EarningsNews CoveragePositive NewsTARAProtara Therapeutics2.3183 of 5 stars$3.52-18.5%$20.40+479.5%+23.9%$129.42MN/A-1.2530News CoverageGap DownHigh Trading VolumeCGENCompugen1.8069 of 5 stars$1.44-2.7%$4.00+177.8%-31.5%$128.50M$27.86M72.0070SLSSELLAS Life Sciences Group0.8171 of 5 stars$1.41+0.7%N/A+28.9%$128.09M$1M-2.0410Gap UpNMRANeumora Therapeutics3.1849 of 5 stars$0.76+0.7%$9.29+1,117.6%-91.6%$123.35MN/A-0.41108SCPHscPharmaceuticals3.725 of 5 stars$2.45-2.4%$14.00+471.4%-44.2%$123.20M$36.33M-1.2930News Coverage Related Companies and Tools Related Companies GLSI Competitors FTLF Competitors EDIT Competitors THTX Competitors LYEL Competitors TARA Competitors CGEN Competitors SLS Competitors NMRA Competitors SCPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CVKD Stock Free CVKD Stock Alerts